Definium Therapeutics News - September 14, 2026
DFTX Announces Positive Phase 3 Results for DT120 in Generalized Anxiety Disorder
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for the treatment of generalized anxiety disorder (GAD)....
🟢 Definium Therapeutics is trading 8.90% up today after DT120 reduced anxiety symptoms in second trial
Definium Therapeutics is trading at $42.50 (+8.90%) after DT120 reduced generalized-anxiety symptoms in a second successful late-stage trial. - The...
Definium's Anxiety Drug Aces a Second Late-Stage Trial — But Can a Psychedelic Pill Justify a $6 Billion Valuation?
Shares of Definium Therapeutics surged 19.3% in pre-market trading to $46.41 after the company reported that its experimental anxiety pill cleared the final...
🟢 Definium Therapeutics Surges 19.35% in Pre-Market Following Positive Phase 3 Panorama Study Results
- Definium Therapeutics is trading 19.35% up in pre-market at $46.41 following the announcement of positive topline results from its Phase 3 Panorama study of...
🟢 Definium Therapeutics is trading 5.61% up in pre-market ahead of September 14, 2026 topline results webcast
Definium Therapeutics is trading at $41.07 (+5.61%) ahead of its September 14, 2026 webcast discussing topline results from the Phase 3 Panorama study in...